However, the frequency of co‐occurring TP53 and KEAP1‐NRF2‐pathway mutations in patients with EGFR‐mutant NSCLC, as well as their impact on the prognosis, remains unknown. This evidence concerns the gene TP53 and non-small cell lung carcinoma.